Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study
Cephalalgia · 2024
DOI: 10.1177/03331024241288875 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cephalalgia, 2024. Verfasst von Paul Triller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeck Foundation.
Abstract (Originalsprache)
Background
Migraine patients unresponsive to calcitonin gene-related peptide (CGRP)(-receptor, -R) monoclonal antibodies (mAbs) may benefit from switching between CGRP(-R) mAbs. However, some patients do not tolerate or respond to any subcutaneous mAbs. This study evaluates the efficacy of the intravenous CGRP mAb eptinezumab in these therapy-refractory patients.
Methods
In this retrospective cohort study, patients with migraine who previously failed erenumab and at least one CGRP mAb (fremanezumab and/or galcanezumab) received eptinezumab 100 mg, followed by a second dose of 100 mg or 300 mg after 12 weeks. Monthly headache days, monthly migraine days, acute medication days, and migraine pain intensity were recorded from standardized headache diaries during the four weeks before the first infusion (baseline), and during weeks 9–12 and 21–24 of treatment. Patient-reported outcomes were analyzed at baseline, weeks 12, and 24.
Results
From January 2023 to February 2024, 41 patients received eptinezumab 100 mg. Of these, 38 (93%) received a second infusion after 12 weeks, with 29 (71%) increasing the dose to 300 mg. The percentage of patients with a ≥30% reduction rate in monthly migraine days was 23.1% at week 12 and 29.7% at week 24. Monthly migraine days decreased from 16.3 ± 8.0 at baseline to 15.4 ± 8.1 days during weeks 9–12 and 14.4 ± 8.0 days during weeks 21–24 ( p = 0.07). During weeks 21–24, 38.5% reported a clinically meaningful reduction in HIT-6 scores and 52.4% in MIDAS scores. No adverse events were reported.
Conclusions
Eptinezumab may be an effective and well-tolerated option for some treatment-refractory migraine patients unresponsive to subcutaneous CGRP-(R) mAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Clinician Scientist Program, Berlin Institute of Health at Charité (BIH), Berlin, Germany.
- Universitätsmedizin Greifswald, Greifswald, Germany.
ORCID-Profile: Paul Triller, Lucas H Overeem, Ja Bin Hong, Uwe Reuter, Bianca Raffaelli
Förderung
- Lundbeck Foundation
Zitieren
APA
Triller, P., Blessing, V. N., Overeem, L. H., Fitzek, M. P., Hong, J. B., Lange, K. S., Reuter, U., & Raffaelli, B. (2024). Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia. https://doi.org/10.1177/03331024241288875
Vancouver
Triller P, Blessing VN, Overeem LH, Fitzek MP, Hong JB, Lange KS, et al. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia. 2024. doi:10.1177/03331024241288875
BibTeX
@article{Triller2024,
author = {Triller, Paul and Blessing, Virginia N and Overeem, Lucas H and Fitzek, Mira P and Hong, Ja Bin and Lange, Kristin S and Reuter, Uwe and Raffaelli, Bianca},
title = {Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241288875}
}
EUVIMED